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The mismatch repair gene MSH3 has been implicated as a genetic modiﬁer of the CAGCTG repeat expansion disorders
Huntington’s disease and myotonic dystrophy type 1. A recent Huntington’s disease genome-wide association study found
rs557874766, an imputed single nucleotide polymorphism located within a polymorphic 9 bp tandem repeat in MSH3/DHFR,
as the variant most signiﬁcantly associated with progression in Huntington’s disease. Using Illumina sequencing in Huntington’s
disease and myotonic dystrophy type 1 subjects, we show that rs557874766 is an alignment artefact, the minor allele for which
corresponds to a three-repeat allele in MSH3 exon 1 that is associated with a reduced rate of somatic CAGCTG expansion
(P = 0.004) and delayed disease onset (P = 0.003) in both Huntington’s disease and myotonic dystrophy type 1, and slower
progression (P = 3.86  107) in Huntington’s disease. RNA-Seq of whole blood in the Huntington’s disease subjects found
that repeat variants are associated with MSH3 and DHFR expression. A transcriptome-wide association study in the
Huntington’s disease cohort found increased MSH3 and DHFR expression are associated with disease progression. These results
suggest that variation in the MSH3 exon 1 repeat region inﬂuences somatic expansion and disease phenotype in Huntington’s
disease and myotonic dystrophy type 1, and suggests a common DNA repair mechanism operates in both repeat expansion
diseases.
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Introduction
Huntington’s disease and myotonic dystrophy type 1
(DM1) are autosomal dominant disorders caused by
CAGCTG trinucleotide repeat expansions. Huntington’s
disease is characterized by a progressive movement dis-
order, cognitive impairment and psychiatric symptoms
(Bates et al., 2014), and DM1 by myotonia, muscular dys-
trophy, cognitive impairment, cardiac conduction defects
and endocrine dysfunction (Harper, 2001). No disease-
modifying treatments are available for either (Bates et al.,
2015; Meola and Cardani, 2015).
Huntington’s disease is caused by a (CAG)n repeat ex-
pansion in HTT exon 1 and DM1 by a (CTG)n expansion
in the 30 untranslated region (UTR) of DMPK (Brook
et al., 1992; Bates et al., 2014). In both, inherited repeat
length is the major determinant of disease course, correlat-
ing inversely with the age at onset and positively with
disease severity. The repeat is unstable, and expansion
during germline transmission results in genetic anticipa-
tion (Hunter et al., 1992; Bates et al., 2014). Repeat
tracts are also unstable in somatic cells, tending to
expand over time, particularly in Huntington’s disease
striatum (Kennedy et al., 2003) and DM1 muscle
(Ashizawa et al., 1993), the most prominently affected
tissues in each disease. Such expansion-biased, age-de-
pendent and tissue-speciﬁc somatic instability is thought
to contribute to disease onset and progression (Kennedy
et al., 2003; Shelbourne et al., 2007; Swami et al., 2009;
Morales et al., 2012).
In mouse models, the DNA mismatch repair proteins
MSH2 and MSH3 are essential for CAGCTG repeat ex-
pansion, and their inactivation limits expansion events and
improves disease phenotype (van den Broek et al., 2002;
Foiry et al., 2006; Dragileva et al., 2009; Pinto et al., 2013;
Tome et al., 2013). In patients with DM1, a candidate gene
association study reported a coding single nucleotide poly-
morphism (SNP) (rs26279, p.A1045T) in MSH3 exon 23
that was associated with the rate of somatic expansion
(Morales et al., 2016). Genome-wide association studies
(GWAS) in patients with Huntington’s disease identiﬁed
variation in DNA repair genes that modify disease course,
and pathway analyses in each study further highlighted
DNA repair (GeM-HD, 2015; Moss et al., 2017; Lee
et al., 2017). Such variants also inﬂuence onset in other
CAG expansion diseases, suggesting a common mechanism
operates in conditions caused by repeat expansion
(Bettencourt et al., 2016). The lead variant in a recent
GWAS linking MSH3 with Huntington’s disease progres-
sion was the imputed SNP rs557874766, which nominally
results in Pro67Ala at the N-terminus (Moss et al., 2017).
However, rs557874766 is located within a 9 bp tandem
repeat in exon 1 of MSH3 and the 50 UTR of the dihydro-
folate reductase gene (DHFR) on the opposite strand. This
repeat is polymorphic in copy number (Nakajima et al.,
1995; Morales et al., 2016) and sequence (Morales,
2006), which led us to hypothesize that rs557874766
could be an alignment artefact. Additionally, the 500-bp
region ﬂanking the MSH3 repeat is highly polymorphic,
containing six SNPs and a 1-bp indel. We conducted tar-
geted Illumina sequencing of the MSH3 exon 1 region in
218 Huntington’s disease and 247 DM1 subjects, which
allowed us to obtain accurate haplotype information for
the region. Using whole blood RNA-Seq in Huntington’s
disease, we investigated whether sequence variation at the
MSH3/DHFR locus inﬂuences their expression.
Materials and methods
Cohorts
The 218 Huntington’s disease subjects were from TRACK-HD
(Tabrizi et al., 2009). The DM1OPTIMISTIC cohort of 247 sub-
jects was from OPTIMISTIC (van Engelen and Consortium,
2015) and the independent DM1CostaRica cohort of 199 sub-
jects was previously reported in Morales et al. (2016).
Progenitor allele length
Progenitor pure CAG length for Huntington’s disease was
determined by MiSeq sequencing (Ciosi et al., 2018). Five sub-
jects were excluded because they were part of a twin pair
(n = 1) or the progenitor CAG length could not be unambigu-
ously identiﬁed (n = 4) (Ciosi et al., unpublished results). DM1
progenitor allele length was determined by small pool PCR
(van Engelen and Consortium, 2015; Cumming et al., in
press). DM1 patients were tested for CCG repeat interrup-
tions, known cis-modiﬁers of CTG repeat stability and disease
phenotype (Cumming et al., 2018, in press).
Phenotypes
Two phenotypes were common to both cohorts: age at onset
and rate of somatic expansion of the pathogenic CAGCTG
repeat. Huntington’s disease age at onset represents onset of
motor symptoms (Tabrizi et al., 2009). DM1 age at onset was
subject self-assessment of the ﬁrst occurrence of symptoms
likely related to DM1 (Cumming et al., in press). Somatic
CAGCTG expansion in blood was previously quantiﬁed in
both cohorts (Ciosi et al., unpublished results; Cumming
et al., in press). For Huntington’s disease MiSeq data, the
measure of somatic expansion was the proportion of reads
in the sample that correspond to somatic expansions (reads
with more CAG repeats than the progenitor allele) relative to
the number of reads obtained for the progenitor allele (Ciosi
et al., unpublished results). For DM1, it was the difference in
number of repeats between the modal allele and the estimated
progenitor allele length (Cumming et al., 2018). In both co-
horts, relative rate of somatic expansion corresponds to the
variation in the measures of somatic expansion that is not
explained by age and CAGCTG repeat length. Positive
values reﬂect a faster rate of somatic expansion.
Two phenotypes were only available for Huntington’s dis-
ease; progression score (Moss et al., 2017) and gene expres-
sion. Progression score was derived for 213 TRACK-HD
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subjects in Ciosi et al. (unpublished results), as described in
Moss et al. (2017). It measures typical Huntington’s disease
progression that is not explained by age and pure CAG repeat
length, with positive scores reﬂecting faster progression. Blood
MSH3 and DHFR expression levels were available for 108
Huntington’s disease subjects (Moss et al., 2017).
Illumina sequencing of MSH3 exon 1
MiSeq amplicon sequencing, adapted from Ciosi et al. (2018),
was used to genotype the MSH3 exon 1 repeat and ﬂanking
variants (Supplementary Fig. 1). The region was ampliﬁed
using locus-speciﬁc primers incorporating Illumina indexed
adaptors (Supplementary Table 1) (Ciosi et al., 2018). PCR
was carried out using 10 ng of blood genomic DNA, 10%
DMSO, 1 mM of each primer, 1 Custom PCR master mix
(Thermo Scientiﬁc, SM0005), 0.048% (v/v) 2-mercaptoethanol
and 0.5 U of Taq polymerase (Sigma) in a total volume of
10 ml. Thermal cycling conditions were: an initial denaturation
at 96C for 5min, followed by 30 cycles of (96C for 45 s),
(60C for 45 s) and (70C for 2min), with a ﬁnal extension at
65C for 1min followed by 70C for 10min. Six hundred
sequencing cycles were run 400 nt forward, 200 nt reverse.
Quality control conﬁrmed 480% of bases had Phred quality
430.
Bioinformatic analyses
Genotyping was conducted on the University of Glasgow
Galaxy platform (heighliner.cvr.gla.ac.uk). Paired-end reads
were merged and aligned to multiple references corresponding
to potential 9 bp repeat alleles (Supplementary material), fol-
lowed by variant calling. For repeat homozygotes, haplotypes
were conﬁrmed from .sam ﬁles using Tablet (Milne et al.,
2013). The Galaxy workﬂow is available at https://www.
myexperiment.org/workﬂows/5087.html. Conservation ana-
lysis used PhastCons and PhyloP (UCSC), with species se-
quence alignment in Clustal Omega.
Transcriptome-wide association
study
The transcriptome-wide association study (TWAS) method
of Gusev et al. (2016) was used to impute cortical gene ex-
pression from 452 dorsolateral prefrontal cortex samples
from the CommonMind Consortium (CMC, 2017) into the
TRACK-HD GWAS of Huntington’s disease progression
(n = 243) (Moss et al., 2017). Following the Gusev et al.
(2016) approach, we tested association between imputed cor-
tical gene expression and Huntington’s disease progression.
Statistical analyses
Linear regression modelling of genotype-phenotype correlation
was conducted in R (R Core Team, 2013). An additive genetic
model was used to score genotypes. For age at onset analysis,
we controlled for CAGCTG repeat length in Huntington’s
disease and DM1, and for repeat interruptions in DM1
(Supplementary Table 4). Meta-analysis of somatic expansion
and age at onset in Huntington’s disease and DM1 was con-
ducted with METAL (Willer et al., 2010). PLINK 1.07 (Purcell
et al., 2007) was used to derive allele frequencies, Hardy-
Weinberg equilibrium (HWE) and linkage disequilibrium.
Haplotype relationships were visualized as a network using
median joining on NETWORK (Bandelt et al., 1999).
Data availability
Data are available from the corresponding author on request.
Results
Rs557874766 is an alignment artefact
We observed 16 MSH3 repeat alleles, differing in sequence
and length from three to nine repeats (Fig. 1A and
Supplementary Table 2). Alleles contained combinations
of ﬁve types of repeat units, with coding potential for pro-
line or alanine (Fig. 1A). They were numbered by repeat
length, sufﬁxed alphabetically by frequency i.e. ‘3a’ repre-
sents the most common three-repeat allele.
The most common allele in both cohorts, 6a (Fig. 1B),
corresponds to the human reference sequence
(NC_000005.10, GRCh38.p12). Illumina sequencing re-
vealed that rs557874766 (Moss et al., 2017) was not a
SNP, but an alignment artefact resulting from the complex
9-bp repeat sequence (Fig. 1C). Individuals with the
rs557874766 minor allele instead carry a three-repeat
allele, 3a, the second most common allele observed in
both cohorts. Two subjects with Huntington’s disease
imputed as homozygous for the rs557874766 major allele
were determined to be heterozygous for the 3a repeat allele
by both Illumina and Sanger sequencing (Supplementary
Fig. 2), highlighting the importance of directly genotyping
such complex loci. We conclude that rs557874766 does
not exist in the form of an SNP and results from incorrect
alignment of the 3a allele to the reference 6a allele
(Fig. 1C).
The MSH3 exon 1 repeat region is poorly conserved be-
tween species, with mean scores of 0.29 [standard deviation
(SD) 0.41] and 0.25 (SD 0.91) in PhastCons and PhyloP,
respectively (Supplementary Table 3). Sequence alignment
of 20 mammalian reference genomes showed most have
two repeats (Supplementary Fig. 3). Together with a four-
and a ﬁve-repeat allele, the 3a allele has been observed in
gorillas and chimpanzees, suggesting 3a is an ancestral
allele in humans (Morales, 2006).
MSH3/DHFR variants are associated
with rate of somatic expansion and
disease phenotypes in Huntington’s
disease and DM1
The 3a allele correlated negatively with relative rate of
somatic expansion in subjects with Huntington’s disease
(P = 0.032) and showed similar effect direction, though
above nominal signiﬁcance, in DM1 (P = 0.053) (Fig. 2
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and Supplementary Table 2). Additionally, 3a was asso-
ciated with delayed age at onset by 1.05 years
(P = 0.0029) and slower progression in Huntington’s dis-
ease by 0.52 units (P = 3.86  107), which corresponds
to 0.37 and 0.10 units per year on the UHDRS total
motor score and total functional capacity, respectively. In
DM1, the association between 3a and age at onset showed
a consistent effect direction, approaching signiﬁcance
(P = 0.061). In meta-analysis, 3a was signiﬁcantly asso-
ciated with relative rate of somatic expansion (P = 0.004)
and age at onset (P = 0.003) in Huntington’s disease and
DM1. Detailed analysis of the relationship between repeat
alleles and phenotypes (Supplementary Table 5) shows that
the 3a allele accounts for the reduced somatic expansion
rate, delayed onset and slower progression observed in
Huntington’s disease. The association with somatic expan-
sion appears to be driven by 3a homozygotes, whereas that
with progression seems to follow an additive pattern with
the number of 3a alleles. For onset, the pattern of associ-
ation is unclear. In DM1, the number of seven-repeat alleles
was associated with reduced expansion rate
(Supplementary Table 5).
In addition to testing repeat allele effects, we also as-
sessed correlation between ﬂanking SNP genotypes and dis-
ease phenotypes. All the ﬂanking variants were in HWE
(Supplementary Table 6) and in strong linkage disequilib-
rium with each other (Fig. 3B). Three variants
(rs151182735, rs10168 and rs2250063) were in nearly
complete linkage disequilibrium with the 3a allele, and as
such were as signiﬁcantly associated with phenotypes
(Fig. 3A and Supplementary Table 6). All three are non-
coding variants 5’ to the repeat and their alternative alleles
are associated with reduced MSH3 and DHFR expression
in the prefrontal cortex (CMC, 2017) and in multiple tis-
sues in GTEx (GTEx, 2015) (Supplementary Table 7).
Three SNPs, rs1105524, rs1650697 and rs1677658, also
Figure 1 MSH3/DHFR 9bp tandem repeat allele structure and frequency observed in Huntington’s disease and DM1 cohorts.
(A) Schematic representation of the 9 bp tandem repeat alleles observed in this study and their coding potential. Repeat units are colour-coded by
DNA and amino acid sequence. Location of the repeat and flanking variants in relation to MSH3/DHFR locus are shown in the top panel. This locus
contains overlapping MSH3 exon 1 and DHFR promoter regions. For both MSH3 and DHFR, the 5’-untranslated region is shown in white and
coding sequence in light grey. The direction of transcription is indicated by arrows for each gene. (B) Repeat allele frequencies observed in
Huntington’s disease (HD) and DM1. Four common alleles, 3a, 6a, 7a and 8a, are observed in Huntington’s disease and DM1 cohorts at similar
frequencies. (C) Schematic showing potential misalignments of 3a and 6a alleles, resulting in the apparent SNP rs557874766, shown in red on the
lower alignment. Black marks in the top alignment represent mismatches that could be created in a similar manner as rs557874766, by mis-
alignment of the 3a and 6a repeat alleles.
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correlated with some phenotypes, though not uniformly
(Fig. 3A and Supplementary Table 6). Rs1105524 and
rs1677658 are non-coding variants, whereas rs1650697
corresponds to Ile79Val. All three are expression quantita-
tive trait loci (eQTL) for MSH3 and DHFR in the pre-
frontal cortex (CMC, 2017) and in multiple tissues in
GTEx (Supplementary Table 7). Previously, in a separate
DM1 cohort (DM1CostaRica), Morales et al. (2016) reported
association between both rs1677658 (P = 0.009) and
rs10168 (P = 0.031) and somatic expansion, though neither
survived correction for multiple testing for the candidate
SNPs analysed. However, the direction of effect for both
SNPs was the same as in the present study, and a signiﬁ-
cant association in meta-analyses with the two DM1 co-
horts (rs1677658 P = 0.03, rs10168 P = 0.004) and all
three DM1 and Huntington’s disease cohorts (rs1677658
P = 8.85  104, rs10168 P = 3.37  104) suggests these
variants inﬂuence somatic expansion (Supplementary
Table 6). Morales et al. (2016) reported an association
between somatic expansion and age at onset, though the
direct effect of MSH3 genotype on age at onset was not
found to be signiﬁcant. In the present study, meta-analyses
of the two DM1 cohorts (rs1677658 P = 0.009, rs10168
P = 0.04) and all three DM1 and Huntington’s disease co-
horts (rs1677658 P = 8  104, rs10168 P = 0.003) found
the MSH3 genotype was signiﬁcantly associated with age at
onset (Supplementary Table 6). Meta-analyses of the three-
repeat allele with all three DM1 and Huntington’s disease
cohorts provide further support for its protective effect on
somatic expansion (DM1OPTIMISTIC + DM1CostaRica
P = 0.004, DM1OPTIMISTIC + DM1CostaRica + Huntington’s
disease P = 3.46  104) and age at onset (DM1OPTIMISTIC
+ DM1CostaRica P = 0.04, DM1OPTIMISTIC + DM1CostaRica
+ Huntington’s disease P = 0.003) (Supplementary Table 2).
The associations of SNPs with phenotypes were condi-
tioned on the effects of MSH3 repeat alleles
(Supplementary Table 8). As rs151182735, rs10168 and
rs2250063 perfectly correlated with 3a, their independent
effects could not be determined (Supplementary Table 6).
With the exception of rs1677658 (linkage disequilibrium
Figure 2 The number ofMSH3 3a repeat alleles is associated with Huntington’s disease and DM1 phenotypes. Boxplots for three
measures of disease phenotype are shown: rate of somatic expansion corrected for the inherited CAGCTG length in Huntington’s disease
(A) and for the inherited CAGCTG length and variant repeats in DM1 (B); age at onset corrected for the inherited CAGCTG length in
Huntington’s disease (C) and DM1 (D); progression score in Huntington’s disease (E). For each dataset, the diamond and horizontal line spanning
the diamond indicate the mean, the box the standard deviation and the whiskers the 95% confidence intervals of the mean. HD = Huntington’s
disease.
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with 3a: r2 = 0.610) and rs1650697 (linkage disequilibrium
with 3a: r2 = 0.143), whose alternative alleles were asso-
ciated with delayed and early age at onset, respectively in
the combined Huntington’s disease and DM1 meta-analysis
(P = 0.015 and P = 0.029; Supplementary Table 8), there
was no signiﬁcant evidence for association between SNPs
and expansion rate, onset or progression independent of
repeat alleles.
Considering variants with minor allele frequency 40.1
and all of the repeat alleles, we observed 25 haplotypes
Figure 3 Variants at the MSH3/DHFR locus are associated with phenotypes in Huntington’s disease and DM1. (A) Bar charts
showing associations between variant genotypes and disease phenotypes: relative rate of somatic expansion and age at onset corrected for the
CAGCTG length and progression score for Huntington’s disease, and rate of somatic expansion and age at onset corrected for the CAGCTG
length and repeat interruptions for DM1. Each bar represents association for a single variant. Red dotted line represents the P = 0.05 significance
threshold. Variant location in relation to the MSH3 exon 1 region is shown in the bottom panel. White box = 5’ untranslated region; grey = coding
sequence; red = MSH3 repeat region; intron is shown by a black line. (B) Linkage disequilibrium heat map for the seven variants flanking the MSH3
repeat. Colour intensity represents the D’ value for each SNP pair. R2 values are indicated in text for each variant pair. (C) Haplotype network for
eight haplotypes with frequency4 0.035 observed at the MSH3 exon 1 region. Circles represent different haplotypes. The size of the circle is
proportional to the number of individuals with a particular haplotype. Each haplotype is connected with the most similar haplotype by a line.
Length of the line represents the number of genotypes that are different between each two haplotypes. Circles are colour coded according to the
repeat allele found on the haplotype.
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in the region, named Hap1 to Hap25 (Supplementary
Table 9). The 3a repeat allele occurs on both Hap1 and
Hap2, which differ only in the presence of the rs1677658
alternative allele on the more common Hap2. Hap1 was
associated with reduced somatic expansion in DM1
(P = 0.032) and slower progression in Huntington’s disease
(P = 0.020), whereas Hap2 was associated with reduced
somatic expansion (P = 0.021) and delayed onset
(P = 4.03  105) in both Huntington’s disease and DM1,
and with slower progression (P = 1.64  105) and reduced
expression of MSH3 (P = 0.024) and DHFR
(P = 1.12  103) in Huntington’s disease (Supplementary
Table 9).
Overall, this analysis clariﬁes the sequence and variants
present in MSH3 exon 1 and demonstrates that MSH3
repeat variants are associated with disease phenotypes in
both Huntington’s disease and DM1.
MSH3 and DHFR expression in blood
is associated with repeat alleles
Each 3a allele was associated with reduced DHFR
expression (P = 2.48  104; Fig. 4C) and homozygosity
for 3a was associated with reduced MSH3 expression
(P = 0.0273; Fig. 4B), whereas each 7a or 8a allele
was associated with increased MSH3 expression
(P = 8.55  104 and P = 8.26  103, respectively). The
sum of MSH3 repeat lengths on both alleles appeared to
correlate with MSH3 (P = 7.00  103) and DHFR expres-
sion (P = 1.76  103), which would suggest increasing
repeat length increases expression of both (Supplementary
Fig. 4). However, a more detailed analysis of MSH3 repeat
alleles (Supplementary Table 5) shows the number of seven-
or eight-repeat alleles is associated with increased expres-
sion of MSH3 (P = 4.53  106), and that this explains the
apparent association with the sum of repeat lengths. In this
relatively small cohort, MSH3 (age at onset P = 0.446, pro-
gression P = 0.440) and DHFR (age at onset P = 0.911,
progression P = 0.284) expression in blood were not them-
selves directly associated with disease phenotype. MSH3
expression was not signiﬁcantly associated with somatic
expansion (P = 0.625), whereas the association of DHFR
expression, while nominally signiﬁcant (P = 0.049), did
not survive correction for the number of phenotypes tested.
In the detailed analysis, the number of three-repeat alleles
was associated with reduced DHFR expression
(P = 2.33  104; Fig. 4C), and this was sufﬁcient to ex-
plain the apparent association of DHFR expression with
other repeat alleles (Supplementary Table 5), including
that observed with increasing total repeat length. DHFR
and MSH3 expression are correlated (r2 = 0.120,
P = 2.06  104; Fig. 4A). However, association between
DHFR and three-repeat alleles remains signiﬁcant after cor-
recting for MSH3 expression (P = 7.51  104), and asso-
ciation between MSH3 and seven- or eight-repeat alleles
remains signiﬁcant after correcting for DHFR expression
(P = 1.30  107). In the best-ﬁtting model for DHFR ex-
pression, the alternative allele at rs1105524 (linkage dis-
equilibrium with 3a: r2 = 0.192) increases and rs1650697
decreases DHFR expression independently of the three-
repeat alleles (Supplementary Table 8). Otherwise, the
repeat allele is the major determinant of MSH3 and
DHFR expression, and there is no evidence of independent
SNP effects.
Figure 4 Association of theMSH3 3a allele withMSH3 and DHFR expression in Huntington’s disease whole blood. Whole blood
RNA-Seq in a subset of 108 Huntington’s disease subjects. (A) Significant correlation between MSH3 and DHFR expression levels (r2 = 0.120,
P = 2.06  104). Grey area around the blue regression line represents 95% confidence interval of the model. (B) Homozygosity for MSH3 3a
repeat allele is associated with lower MSH3 expression in blood (P = 0.028). (C) MSH3 3a repeat allele is associated with lower DHFR expression
(P = 2.33  104). Rpkm = reads per kilobase of transcript per million mapped reads. In boxplots, the diamond and horizontal line spanning the
diamond indicate the mean, the box indicates the standard deviation and the whiskers indicate the 95% confidence intervals of the mean.
1882 | BRAIN 2019: 142; 1876–1886 M. Flower et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/7/1876/5520687 by U
niversity C
ollege London user on 30 June 2019
MSH3 expression in cortex is
associated with onset and progression
in Huntington’s disease
In a TWAS, increased expression of both MSH3 and
DHFR in prefrontal cortex (CMC, 2017) was associated
with faster progression in TRACK-HD (Moss et al.,
2017) at similar levels of signiﬁcance (P = 2.52  106
and P = 4.08  106, respectively; Supplementary Table
10), making it difﬁcult to distinguish which is more func-
tionally relevant. This ties in with the observation that
SNPs signiﬁcantly associated with somatic expansion, age
at onset and progression (Supplementary Table 6) were
eQTLs for both MSH3 and DHFR in CMC data.
Notably, however, increased MSH3 expression was signiﬁ-
cantly associated with early onset (P = 1.71  103) in a
TWAS of the GeM dataset (GeM-HD, 2015), while
DHFR expression was not signiﬁcantly associated with
onset (Supplementary Table 10). This favours MSH3 over
DHFR expression as a modiﬁer of Huntington’s disease
course.
Discussion
MSH3 has recently been identiﬁed as a genetic modiﬁer of
somatic instability in DM1 (Morales et al., 2016), and pro-
gression in Huntington’s disease (Moss et al., 2017). The
MSH3 signal in the GWAS of Huntington’s disease pro-
gression was driven by an imputed SNP, rs557874766,
located within a 9 bp tandem repeat sequence in exon 1
of MSH3, which is also in the 50 UTR of DHFR on the
opposite strand. MSH3 and DHFR are organized head-to-
head, transcribed in opposite directions and are regulated
by the same promoter. Here we demonstrate that
rs557874766 is an alignment artefact and corresponds to
a three-repeat allele, 3a, which was the shortest repeat
allele observed and is likely ancestral. At the protein
level, in silico modelling predicts that 6a results in the
gain of a surface -helix (Kallberg et al., 2012) at the N-
terminus of MSH3.
A total of 16 MSH3 repeat alleles were observed, varying
in sequence and length from three to nine repeats. Repeat
alleles 6a and 3a are the ﬁrst and second most common in
this European cohort, though previous studies suggest a
seven-repeat allele may be second most common in East
Asian populations (Nakajima et al., 1995). In
Huntington’s disease, 3a was associated with reduced som-
atic expansion, delayed onset and slower progression. In
DM1, each 3a allele showed a trend towards reduced som-
atic expansion and delayed onset but was signiﬁcantly asso-
ciated with both measures in meta-analysis of Huntington’s
disease and DM1. Longer seven-repeat alleles were asso-
ciated with reduced somatic expansion only in DM1.
Whether this reﬂects a subtle difference in MSH3 biology
between the two disorders, or simply a sampling error, re-
mains undetermined.
The MSH3 repeat lies between binding domains for
PCNA (Clark et al., 2000) and EXO1 (Schmutte et al.,
2001), both of which are involved in mismatch repair
(MMR) (Kleczkowska et al., 2001). PCNA is a sliding
clamp that participates in DNA replication, but in MMR
it delivers MSH proteins to mismatches and increases bind-
ing speciﬁcity (Flores-Rozas et al., 2000). EXO1 excises the
daughter strand after mismatch recognition, as well as
being involved in end resection during homologous recom-
bination (Goellner et al., 2015). The MSH3 repeat region is
poorly conserved between species, with other mammals
having between zero and ﬁve repeats. This lack of evolu-
tionary constraint suggests functional redundancy in the
MMR pathway and a lack of a major effect of N-terminal
MSH3 variation outside the context of repeat expansion
disease. Unlike other MMR components, germline hetero-
zygous MSH3 mutations are not associated with increased
risk of cancer, most likely because MSH2/MSH6 can also
initiate repair at replication errors (Edelmann et al., 2000;
Jiricny, 2006; Haugen et al., 2008).
Three non-coding variants 5’ of the repeat were in near
complete linkage disequilibrium with 3a, so it is not pos-
sible to determine their independent effects on disease
phenotypes. All three are associated with reduced MSH3
expression in multiple tissues, including cortex (CMC and
GTEx). Controlling for repeat alleles, no SNPs were signiﬁ-
cantly associated with phenotypes, except the intronic
rs1677658 and the exon 1 rs1650697 variants, which con-
tributed to delayed or early onset, respectively in the com-
bined Huntington’s disease and DM1 dataset. Rs1677658
was associated with reduced MSH3 and DHFR expression
(CMC and GTEx), whereas rs1650697 was associated with
increased DHFR in Huntington’s disease blood, as well as
multiple tissues in GTEx. Hap2, the MSH3 haplotype most
signiﬁcantly linked with reduced somatic expansion and
delayed onset in Huntington’s disease and DM1, and
with slower progression in Huntington’s disease, contains
the 3a allele, along with alternative alleles of non-coding
variants rs151182735, rs10168 and rs2250063, which are
in complete linkage disequilibrium with it, and rs1677658.
It is thus difﬁcult to assess which (if any) MSH3 variants
(repeats or SNPs) are driving associations with disease
phenotypes, and further investigation in a larger sample is
warranted.
Whole blood transcriptomic analysis in a subset of the
Huntington’s disease patients found the 3a allele was asso-
ciated with reduced expression of MSH3 and DHFR, and
seven- or eight-repeat alleles with increased MSH3 expres-
sion. DHFR, which shares a promoter with MSH3
(Drummond, 1999), is a ubiquitously expressed enzyme
involved in purine, thymidylic acid and amino acid synthe-
sis, but has not previously been implicated in Huntington’s
disease pathogenesis. Our TWAS found that increased ex-
pression of MSH3 and DHFR in cortex are associated with
faster Huntington’s disease progression (Moss et al., 2017).
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While MSH3 expression was signiﬁcantly associated with
early onset in our GeM TWAS (P = 1.71  103) (GeM-
HD, 2015), DHFR expression was not associated with dis-
ease course. This is consistent with Huntington’s disease
mouse brain, in which expression of MSH3, but not
DHFR, correlates with somatic expansion (Tome et al.,
2013). Neither MSH3 nor DHFR expression in blood
was signiﬁcantly associated with somatic expansion, onset
or progression in this sample. However, investigation in a
larger sample, or in a more relevant tissue, such as stri-
atum, would be of interest.
Collectively, our results suggest the MSH3 3a repeat
allele reduces somatic expansion and improves phenotype
in both Huntington’s disease and DM1, potentially through
altering MSH3 expression levels. However, given the prox-
imity of the repeat region to MMR protein binding do-
mains, the 3a allele could also alter MSH3 function in
the recognition and repair of insertion-deletion loops,
double-strand breaks or single-strand annealing (Lyndaker
and Alani, 2009; Schmidt and Pearson, 2016). Repetitive
DNA sequences form unusual secondary structures such as
slipped strands, hairpin loops, G-quadruplexes and R-loops
(Mirkin, 2007; Neil et al., 2017), the stability of which
correlates with expansion (Gacy et al., 1995). MSH3 may
recognize these structures (Owen et al., 2005) and initiate
repair, during which out of register synthesis could result in
repeat expansion (Khan et al., 2015; Neil et al., 2017). This
preliminary study elucidates variation in MSH3 that modi-
ﬁes Huntington’s disease and identiﬁes the same signal in
an independent trinucleotide repeat disease. Though
beyond the scope of the present study, in the future it
will be important to replicate these ﬁndings in additional
independent cohorts for each disease. Together, these re-
sults suggest a common mechanism, involving somatic ex-
pansion, operates in vivo in distinct trinucleotide repeat
diseases to inﬂuence disease course. Therefore, modulation
of MSH3 has signiﬁcant therapeutic potential in a range of
diseases caused by repeat expansions.
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